

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.30US02	Application Number: 08/918,874
	Applicant: Ashkenazi et al.	
	Filing Date: August 26, 1997	Group Art Unit: 1646

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
1	Blast Results (A-1 - A55)	
2	Blast Results (B-1 - B23)	
3	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- $\kappa$ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain," <u>Immunity</u> , 7:813-820 (1997).	
4	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <u>J. Biol. Chem.</u> , 273:14363-14367 (1998).	
5	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <u>FEBS Letters</u> , 424:41-45 (1998).	
6	Schneider et al., "Characterization of two receptors for TRAIL," <u>FEBS Letters</u> , 416:329-334 (1997).	
7	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <u>Current Biology</u> , 7:693-696 (1997).	

EXAMINER <u>John D. [Signature]</u>	DATE CONSIDERED <u>11-30-98</u>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	